The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a multicenter retrospective cohort study evaluating the safety and efficacy of FTD/TPI plus ramucirumab in advanced gastric cancer (HGCSG2302).
 
Ayumu Yoshikawa
No Relationships to Disclose
 
Takeaki Nakamura
No Relationships to Disclose
 
Kentaro Sawada
No Relationships to Disclose
 
Atsushi Ishiguro
No Relationships to Disclose
 
Iori Motoo
No Relationships to Disclose
 
Yuki Sonoda
No Relationships to Disclose
 
Kazuhiro Suzuki
No Relationships to Disclose
 
Hiroshi Nakatsumi
Honoraria - Daiichi Sankyo; Viatris
 
Ayumu Hosokawa
Honoraria - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Nihon Zouki; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Chugai Pharma (Inst)
 
Takahiro Ishii
No Relationships to Disclose
 
Ken Ito
No Relationships to Disclose
 
Michio Nakamura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Daiichi Sankyo; Lilly Japan; Merck; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Takeda (Inst); Zeria Pharmaceutical (Inst)
 
Kazuteru Hatanaka
No Relationships to Disclose
 
Takashi Meguro
No Relationships to Disclose
 
Susumu Sogabe
No Relationships to Disclose
 
Yusuke Sasaki
No Relationships to Disclose
 
Shintaro Nakano
No Relationships to Disclose
 
Tetsuhito Muranaka
Honoraria - AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb; EA Pharma; Lilly; Novartis; Novo Nordisk; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD K.K; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb Co.; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); DAIICHI SANKYO CO., LTD.; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; MSD K.K.; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon Pharma Co., Ltd.; Sysmex; Taiho Pharmaceutical; Yakult Honsha